Harvard Bioscience, Inc. (HBIO) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Harvard Bioscience, Inc. (HBIO) Healthcare & Pipeline Overview

Harvard Bioscience, Inc. provides a range of tools and technologies for life science research, focusing on drug discovery and pre-clinical testing. With a global presence, the company serves pharmaceutical, biotechnology, academic, and government sectors, offering instruments and services under established brand names.

What Is the Investment Thesis for HBIO?

Harvard Bioscience, Inc. presents a mixed investment profile. The company's established presence in the life science research tools market and its diverse product portfolio offer some stability. With a market capitalization of $36.8M and a P/E ratio of 8.83, the company's valuation reflects both its potential and its challenges. A gross margin of 53.0% indicates pricing power, while a negative profit margin of -65.5% raises concerns about profitability. Free cash flow of $0.01 billion suggests some financial flexibility. Growth catalysts include expanding into emerging markets and introducing innovative products. However, risks include intense competition and the potential for technological obsolescence. Investors should closely monitor the company's ability to improve profitability and capitalize on growth opportunities.

Based on FMP financials and quantitative analysis

HBIO Key Highlights

Market capitalization of $36.8M indicates a small-cap company with potential for growth but also higher risk.

• P/E ratio of 8.83 suggests the company may be undervalued compared to its earnings, but should be viewed in context of negative profit margins.
• Gross margin of 53.0% demonstrates the company's ability to maintain profitability on its products before operating expenses.
• Free cash flow of $0.01 billion provides financial flexibility for investments in growth initiatives or acquisitions.
• Beta of 1.50 indicates the stock is more volatile than the market, suggesting higher potential gains but also increased risk.

Who Are HBIO's Competitors?

HBIO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are HBIO's Key Strengths?

Established brand names in the life science research market.

• Diverse product portfolio catering to various research applications.
• Global presence with sales in multiple countries.
• Strong relationships with key research institutions.

What Are HBIO's Weaknesses?

Negative profit margin indicates profitability challenges.

• Small market capitalization limits financial flexibility.
• High beta suggests increased stock volatility.
• Dependence on research funding and grants.

What Could Drive HBIO Stock Higher?

Potential for new product launches in cellular and molecular analysis tools.

• Expansion into emerging markets, particularly in Asia-Pacific.
• Strategic partnerships with research institutions and distributors.

What Are the Key Risks for HBIO?

Financial-distress signal — its Altman Z-Score of -2.55 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-73.0%) — the business is not currently generating profit on shareholder capital.
• Intense competition from larger companies with greater resources.
• Technological advancements rendering existing products obsolete.
• Economic downturns leading to reduced research funding.
• Negative profit margin impacting financial stability.

What Are the Growth Opportunities for HBIO?

• Expanding into emerging markets, particularly in Asia-Pacific, offers a significant growth opportunity. The increasing investment in life science research in countries like China and India presents a large addressable market for Harvard Bioscience's products. Establishing strategic partnerships with local distributors and research institutions can facilitate market entry and accelerate revenue growth. This expansion could contribute to a 10-15% increase in annual revenue over the next 3-5 years.
• Developing and launching innovative products that address unmet needs in the pre-clinical research market can drive revenue growth. Investing in R&D to create advanced tools for cellular and molecular analysis, such as high-throughput screening systems and advanced imaging technologies, can attract new customers and increase market share. Successful product launches could generate an additional $5-10 million in annual revenue within 2-3 years.
• Offering comprehensive service and support solutions, including instrument maintenance, training, and consulting, can enhance customer loyalty and generate recurring revenue. Providing value-added services differentiates Harvard Bioscience from competitors and strengthens customer relationships. Service revenue could account for 15-20% of total revenue within the next 5 years.
• Acquiring complementary businesses or technologies can expand Harvard Bioscience's product portfolio and market reach. Targeting companies with innovative technologies or established customer bases in adjacent markets can create synergies and accelerate growth. Strategic acquisitions could add $10-20 million in annual revenue within 3-5 years.
• Leveraging digital marketing and e-commerce platforms to reach a wider audience and streamline the sales process can improve efficiency and drive revenue growth. Investing in online marketing campaigns, search engine optimization, and a user-friendly e-commerce website can attract new customers and increase online sales. Digital initiatives could contribute to a 5-10% increase in annual revenue within 2-3 years.

What Threats Does HBIO Face?

• Intense competition from larger players in the industry.
• Technological obsolescence and the need for continuous innovation.
• Economic downturns affecting research funding.
• Regulatory changes impacting the life science industry.

What Are HBIO's Competitive Advantages?

• Established brand reputation (Harvard Apparatus, DSI, etc.)
• Specialized product portfolio catering to niche research needs.
• Long-standing relationships with research institutions.
• Proprietary technologies and intellectual property.

What Does HBIO Do?

Founded in 1901 and headquartered in Holliston, Massachusetts, Harvard Bioscience, Inc. has evolved into a global provider of specialized tools and technologies for life science research. The company's origins lie in producing physiological recording equipment, and it has since expanded its portfolio through organic growth and strategic acquisitions. Today, Harvard Bioscience develops, manufactures, and markets a diverse range of products, including cellular and molecular technology instruments, such as syringe and peristaltic pumps, as well as instruments and accessories for tissue and organ-based lab research, encompassing surgical products, infusion systems, and behavior research systems. Additionally, the company offers spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. These products are crucial for fundamental research, discovery, and pre-clinical testing in drug development. Harvard Bioscience markets its offerings through direct sales, websites, catalogs, and distributors, reaching research scientists in pharmaceutical and biotechnology companies, universities, hospitals, government laboratories, and contract research organizations. Key brands include Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS.

What Products and Services Does HBIO Offer?

• Develops and manufactures cellular and molecular technology instruments.
• Offers instruments for tissue and organ-based lab research.
• Provides surgical products and infusion systems.
• Creates behavior research systems.
• Offers spectrophotometers and microplate readers.
• Manufactures amino acid analyzers and gel electrophoresis equipment.
• Produces electroporation and electrofusion instruments.
• Develops data acquisition systems for cellular analysis.

How Does HBIO Make Money?

• Develops and manufactures specialized research tools and instruments.
• Sells products directly to research scientists and institutions.
• Utilizes distributors to expand market reach.
• Provides service and support for its products.

What Industry Does HBIO Operate In?

Harvard Bioscience operates in the medical instruments and supplies industry, which is characterized by continuous innovation and demand driven by pharmaceutical and biotechnology research. The industry is experiencing growth due to increasing R&D spending and advancements in drug discovery. Competition is intense, with companies vying for market share through product differentiation and strategic partnerships. Harvard Bioscience's focus on pre-clinical research tools positions it to capitalize on the growing need for efficient and effective drug development processes.

Who Are HBIO's Key Customers?

• Pharmaceutical and biotechnology companies
• Universities and hospitals
• Government laboratories
• Contract research organizations

Company Profile

Harvard Bioscience, Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Holliston, US. The company is led by CEO John D. Duke. HBIO has traded publicly since 2000.

Return on equity for Harvard Bioscience, Inc. stands at -73.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -12.6%, showing how much profit it generates from its asset base. Its free cash flow yield is 5.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.99 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -35.6%, the inverse of the P/E and a quick read on earnings relative to price.

HBIO Valuation & Market Position

With a $36.8M market cap, Harvard Bioscience, Inc. sits in the micro-cap segment of the market. Analyst price targets span from $6.00 to $6.00, with a consensus of $6.00. At the current price of $8.16, that implies roughly 26% downside from the consensus target. Relative to its peer group, HBIO's quantitative score of 26/100 is below the peer average of 43/100.

Quarterly Financial Performance: Harvard Bioscience, Inc.

Revenue for Harvard Bioscience, Inc. came in at $22.7M during Q2 FY2026, a 9.5% improvement versus the preceding quarter. The company recorded a net loss of $2.9M, with diluted EPS of $-0.64. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, HBIO averaged $-0.58 in diluted EPS.

Harvard Bioscience, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -2.55 places it in the distress zone, a signal of elevated financial risk.

Harvard Bioscience, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 204.8% below estimates on average.

Over the past six months, Harvard Bioscience, Inc. insiders filed 12 SEC Form 4 transactions — 0 sales and 12 purchases. On net that is roughly 229K shares acquired (about $202K) — insiders putting money in tends to read as conviction.

HBIO Financials

HBIO Latest News

HBIO Analyst Consensus

HBIO MoonshotScore

HBIO Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources